Current Issue

VOL 12 NO 4 • MAY/JUN 2021

This issue’s cover illustration depicts ibrutinib binding to cysteine remnants at position Cys 481 on Bruton tyrosine kinase (BTK). BTK is one of the essential enzymes downstream on the BCR signaling pathway. BTK leads to the growth and proliferation of malignant B cells. Targeting the inhibition of BTK has dramatically changed the treatment of B-cell malignancies, including chronic lymphocytic leukemia, mantle cell lymphoma, and marginal zone lymphoma. Artwork by Alexandra Webber Baker © 2021, DNA Illustrations, Inc., Asheville, North Carolina.


Quality Improvement Projects and Clinical Research Studies

Beth Faiman, PhD, MSN, APRN-BC, AOCN®, FAAN

Every day, I witness firsthand the amazing things that advanced practitioners and nurse scientists accomplish. Through the conduct of quality improvement (QI) projects and clinical research studies, advanced practitioners and nurse scientists have the opportunity to contribute exponentially not o...

Research and Scholarship

Patients’ Communication Preferences Around Cancer Symptom Reporting During Cancer Treatment: A Phenomenological Study

Sharyn Carrasco, PhD, RN

Patients with cancer experience symptoms from both their disease and treatment, yet clinicians are unaware of 50% to 80% of their patients’ symptoms (Epstein & Street, 2007; Farrell et al., 2001; Ryan et al., 2005). For most cancer patients, symptoms are poorly documented and their impacts ar...

Research and Scholarship

Palliative Integration Into Ambulatory Oncology: An Advance Care Planning Quality Improvement Project

Amanda Hudson Lucas,(1) DNP, RN, ACNS-BC, ACHPN, and Amy Dimmer,(2) DNP, RN, ACCNS-AG

A diagnosis of incurable cancer can result in a loss of control and heightened awareness of mortality, necessitating reflection on life’s priorities (García-Rueda et al., 2016). Advance care planning (ACP) discussions represent a patient-centered experience proven to facilitate a review of end-of...

Review Article

Management of Hematologic Adverse Events Associated With Immune Checkpoint Inhibitors

Barbara Barnes Rogers, CRNP, MN, AOCN®, ANP-BC, Carolyn Zawislak, MPAS, PA-C, and Victoria Wong, PA-C

Immune checkpoint inhibitors (ICIs) target suppressor receptors, including cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1), which are located on the surface of immune cells. Since the activated T cells are not antigen specific, blockade of the immun...

Review Article

Ginseng for the Management of Cancer-Related Fatigue: An Integrative Review

Emily A. Lemke, DNP, AGPCNP-BC, AOCNP®

Cancer-related fatigue (CRF) is one of the most prevalent, debilitating symptoms, affecting a majority of cancer patients (up to 99%) worldwide and potentially persisting for up to 10 years after treatment (Gupta et al., 2007; Liu et al., 2012; Neefjes et al., 2013). The National Comprehensive Ca...

Grand Rounds

Essential Thrombocythemia in a 15-Year-Old Female: Presentation, Workup, and Treatment Considerations in the Pediatric Population

Crystal Flagg, MPAS, PA-C, and Brad Pierce, MPAS, PA-C

Case Study A 15-year-old white female with no significant past medical or surgical history presented to her primary care provider following an episode of collapse without loss of consciousness and with associated symptoms of confusion, dizziness, headache, and vomiting with neurologic symptoms, i...

Practice Matters

Practical Considerations for Integrating Biosimilars Into Clinical Practice

Megan B. May,(1) PharmD, BCOP, Kate Deen Taucher,(2) PharmD, MHA, BCOP, and Wendy H. Vogel,(3) MSN, FNP, AOCNP®

A biosimilar product is highly similar to a U.S. Food & Drug Administration (FDA)-approved biologic product and does not have clinically meaningful differences in regards to safety, purity, and potency (FDA, 2018). Multiple surveys reveal health-care providers have inadequate knowledge about ...

Prescriber's Corner

A Review of the Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies

Donald C. Moore,(1) PharmD, BCPS, BCOP, DPLA, and Daniel Thompson,(2) PharmD

Targeting the B-cell receptor (BCR) signaling pathway has become an area of interest in the development of pharmacotherapy to treat B-cell malignancies. The BCR pathway plays a role in the growth, proliferation, and survival of normal and malignant B cells (Kenkre & Khal, 2012). One of the es...

Section Seperator
Section Seperator
Section Seperator
Section Seperator
Copyright © 2010-2021 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.